Oncology Institute IncNASDAQ:TOI
- LAST PRICE0.6779
- TODAY'S CHANGE (%)-0.0186 (-2.6705%)
- Bid / Lots0.6200/ 45
- Ask / Lots0.8000/ 3
- Open / Previous Close0.6800 / 0.6965
- Day Range
- 52 Week Range
- Volume149,600
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TOI |
|---|---|---|
| 09:32 ET | 664 | 0.68 |
| 09:54 ET | 3214 | 0.68 |
| 09:56 ET | 250 | 0.68 |
| 09:59 ET | 100 | 0.68 |
| 10:03 ET | 1000 | 0.7098 |
| 10:06 ET | 300 | 0.7098 |
| 10:08 ET | 100 | 0.68 |
| 10:21 ET | 4204 | 0.67 |
| 10:35 ET | 3030 | 0.7118 |
| 10:46 ET | 1828 | 0.7118 |
| 10:48 ET | 100 | 0.6888 |
| 11:08 ET | 2000 | 0.6596 |
| 11:22 ET | 100 | 0.665 |
| 11:29 ET | 227 | 0.6749 |
| 11:33 ET | 227 | 0.6749 |
| 11:45 ET | 100 | 0.665 |
| 11:47 ET | 1000 | 0.6651 |
| 11:49 ET | 173 | 0.665 |
| 12:50 ET | 200 | 0.6324 |
| 12:52 ET | 161 | 0.683499 |
| 01:08 ET | 100 | 0.63 |
| 01:14 ET | 100 | 0.64 |
| 01:30 ET | 100 | 0.63 |
| 01:42 ET | 30100 | 0.6302 |
| 01:44 ET | 100 | 0.63 |
| 01:50 ET | 100 | 0.63 |
| 01:53 ET | 106 | 0.63 |
| 01:57 ET | 111 | 0.63 |
| 02:09 ET | 110 | 0.63 |
| 02:11 ET | 500 | 0.66 |
| 02:27 ET | 2000 | 0.63 |
| 02:47 ET | 360 | 0.64755 |
| 02:49 ET | 100 | 0.6723 |
| 03:07 ET | 9257 | 0.6574 |
| 03:09 ET | 2982 | 0.6401 |
| 03:16 ET | 3705 | 0.6672 |
| 03:18 ET | 1500 | 0.67 |
| 03:21 ET | 4300 | 0.67 |
| 03:32 ET | 320 | 0.65 |
| 03:41 ET | 5644 | 0.685 |
| 03:45 ET | 3045 | 0.685 |
| 03:52 ET | 500 | 0.6478 |
| 03:54 ET | 200 | 0.6796 |
| 03:56 ET | 3948 | 0.682 |
| 03:57 ET | 900 | 0.682 |
| 03:59 ET | 3231 | 0.6779 |
Mar 20, 2023
--Guggenheim Adjusts Oncology Institute's Price Target to $3 From $6, Keeps Buy Rating, from 10:09AM ET on Monday Mar 20, 2023 by MT Newswires
10:09AM ET on Monday Mar 20, 2023 by MT Newswires
Mar 17, 2023
CORRECTED-BRIEF-(OFFICIAL)- Oncology Institute Reports Fourth Quarter And Full Year 2022 Financial Results (March 9), from 7:35AM ET on Friday Mar 17, 2023 by Thomson Reuters
7:35AM ET on Friday Mar 17, 2023 by Thomson ReutersCORRECTED-BRIEF-(OFFICIAL)-Oncology Institute Q4 revenue USD 71 million (Mar.9), from 6:40AM ET on Friday Mar 17, 2023 by Thomson Reuters
6:40AM ET on Friday Mar 17, 2023 by Thomson Reuters-- Earnings Flash (TOI) TOI MANAGEMENT LLC Posts Q4 Revenue $71.4M, from 4:35AM ET on Friday Mar 17, 2023 by MT Newswires
4:35AM ET on Friday Mar 17, 2023 by MT Newswires
Mar 16, 2023
CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023, from 8:08PM ET on Thursday Mar 16, 2023 by GlobeNewswire
8:08PM ET on Thursday Mar 16, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oncology Institute Inc | 50.5M | -513.6x | --- |
Sonida Senior Living Inc | 45.3M | -0.7x | --- |
CNL Healthcare Properties Inc | 43.5M | -30.0x | --- |
Exagen Inc | 40.9M | -0.9x | --- |
Star Equity Holdings Inc | 14.1M | -1.8x | --- |
New York Health Care Inc | 38.9M | 0.0x | --- |
Company Information
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices that serve patients at approximately 67 clinic locations across 11 markets and four states throughout the United States. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, and dispensary, clinical trial services, radiation, programs like outpatient stem cell transplants and transfusions, along with 24/7 patient support. It offers cutting-edge treatment through clinical trials. It also offers convenient, safe appointments via telehealth. The Company through Innovative Clinical Research Institute, LLC (ICRI), provides and manages clinical trial services and research for the benefit of cancer patients. The Company's segment includes patient care, dispensary, and clinical trials & other. Its managed clinics primarily serve adult and senior cancer patients in markets that have Medicare Advantage (MA) plans.
Contact Information
- Headquarters
- 18000 Studebaker Rd, Suite 800CERRITOS, CA, United States 90703
- Phone
- 562-735-3226
- Fax
- 302-636-5454
Executives
- President
- Daniel Virnich
- Chief Executive Officer, Director
- Brad Hively
- Chief Financial Officer
- Mihir Shah
- Chief Operating Officer
- Matthew Miller
- Chief Medical Officer
- Yale Podnos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.5M |
|---|---|
Revenue (TTM) | $252.5M |
Shares Outstanding | 74.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $1.68 |
P/E Ratio | -513.6x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | 11.1x |
Operating Margin | -32.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
